GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2015
Anaplastic Thyroid Carcinoma, Version 2.2015.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment and Management of Anaplastic Thyroid Carcinoma: Appraisal of Clinical Practice Guidelines.The Journal of laryngology and otology · 2025Pooled it
- Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients.Annals of surgical oncology · 2018Pooled it
- Photon irradiation prompts autophagy in anaplastic thyroid cancer.BMC cancer · 2026Article
- Metastatic Anaplastic Thyroid Carcinoma Presenting with Gastrointestinal Bleeding: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Cascade-penetrating domino-ferroptosis nano inducer synergizes with sonodynamic therapy for anaplastic thyroid cancer.Materials today. Bio · 2025Article
- The endoplasmic reticulum stress-ferroptosis reciprocal signaling orchestrates anti-tumor effect of anlotinib in anaplastic thyroid cancer.Cancer cell international · 2025Article
- Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma.Frontiers in endocrinology · 2025Article
- A Novel Scoring System for AUS Thyroid Nodule.International journal of endocrinology · 2025Article
- Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance.Frontiers in oncology · 2025Article
- New Horizons of Biomarkers in Metastatic Thyroid Cancer.Journal of Cancer · 2025Review
- SIRT7 promotes the proliferation and migration of anaplastic thyroid cancer cells by regulating the desuccinylation of KIF23.BMC cancer · 2024Article
- Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.Journal of nanobiotechnology · 2023Review
- Clinicopathological profile and management of thyroid carcinoma: a Sub-Saharan country experience.Thyroid research · 2023Article
- Anti-Proliferative Effect of Radiotherapy and Implication of Immunotherapy in Anaplastic Thyroid Cancer Cells.Life (Basel, Switzerland) · 2023Article
- Contrast-enhanced CT-based Radiomics for the Differentiation of Anaplastic or Poorly Differentiated Thyroid Carcinoma from Differentiated Thyroid Carcinoma: A Pilot Study.Scientific reports · 2023Article
- Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines.Drug design, development and therapy · 2023Article
- Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.Endocrine · 2022Article
- Article
- Molecular Imaging and Theragnostics of Thyroid Cancers.Cancers · 2022Review
- A-Kinase Interacting Protein 1 Knockdown Restores ChemosensitivityFrontiers in oncology · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.